Omeros (OMER) Profit After Tax (2010 - 2026)
Omeros (OMER) posted Profit After Tax of $56.1 million for Q1 2026, down 31.09% sequentially from $81.3 million in Q4 2025, and up 249.23% YoY from $16.1 million in Q1 2025.
Omeros (OMER) Profit After Tax (2010 - 2026) Analysis & Trends
Omeros has reported Profit After Tax for 17 years, with the latest figure at $56.1 million in Q1 2026.
- Quarterly Profit After Tax rose 249.23% year-over-year to $56.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 143.15% YoY) and the FY2025 annual result came in at -$3.4 million, up 98.17% from the prior year.
- Profit After Tax slipped to $56.1 million in Q1 2026 per OMER's latest filing, from $81.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at $183.4 million in Q4 2022 and troughed at -$66.2 million in Q4 2023.
- A 5-year average of -$15.8 million and a median of -$37.1 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 274.4% in 2022, then slumped 136.08% in 2023.
- Over 5 years, Profit After Tax stood at $183.4 million in 2022, then sank by 136.08% to -$66.2 million in 2023, then gained by 13.6% to -$57.2 million in 2024, then soared by 242.29% to $81.3 million in 2025, then sank by 31.09% to $56.1 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $56.1 million, $81.3 million, and -$30.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 13.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.23 Mn |
| Mar 31, 2026 | 56.06 Mn |
| Dec 31, 2025 | 81.35 Mn |
| Sep 30, 2025 | -30.92 Mn |
| Jun 30, 2025 | -25.42 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -57.17 Mn |
| Sep 30, 2024 | -37.11 Mn |
| Jun 30, 2024 | -56.04 Mn |
| Mar 31, 2024 | -37.18 Mn |
| Dec 31, 2023 | -66.18 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -37.29 Mn |
| Mar 31, 2023 | -33.70 Mn |
| Dec 31, 2022 | 183.40 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -30.85 Mn |
| Mar 31, 2022 | -33.01 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -44.28 Mn |